Most studies on the primary prevention of cardiovascular disease (CVD) have been limited to patients at high CVD risk. We assessed the achievement of treatment goals for CVD risk factors among patients with a substantial variation in CVD risk.
Introduction
Despite compelling evidence for the efficacy of primary prevention, 1 -3 cardiovascular disease (CVD) remains the main cause of mortality in Europe. 2, 4 One important reason could be the insufficient implementation of evidence-based CVD prevention guidelines. 2 Some country-specific studies, mostly conducted in high-risk patients, have shown that control of CVD risk factors is sub-optimal despite widespread treatment 5 -12 but the few multinational surveys available have focused on single risk factors, 13, 14 did not directly measure risk factors at the study visit, 15 or were limited to patients with pre-existing CVD or at high or very high risk of CVD. 16 -19 Hence, there is limited comparable information on management and control of CVD risk factors in primary prevention patients over a wider range of global CVD risk across Europe. These patients, however, comprise a large fraction of all patients attended in primary care and, because of their large number, give rise to a large proportion of CVD events in the population. 20 In order to provide a comprehensive assessment of clinical practice in the primary prevention of CVD across Europe, we studied patients with major CVD risk factors but with varying degrees of CVD risk. In these patients, we assessed the achievement of treatment goals for the main CVD risk factors. We also estimated these patients' residual risk on treatment, determined by the SCORE equation. 21 -23 The SCORE equation for estimating CVD risk is a central element in the European prevention guidelines, but it has yet not been used in any major international study.
Methods

Study design and participants
The European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (EURIKA) 24 was a cross-sectional study conducted simultaneously in 12 European countries (Austria, Belgium, France, Germany, Greece, Norway, Russia, Spain, Sweden, Switzerland, Turkey, and the UK; ClinicalTrials.gov identifier, NCT00882336). These countries were selected to represent the complete spectrum of CVD risk across Europe, as well as a variety of different healthcare systems. Data collection started in May 2009 and ended in January 2010. Participating physicians were selected to represent practitioners involved in CVD prevention in primary care centres or outpatient clinics in each country. OneKey, a large database containing information on the characteristics of practicing physicians (http:// crm.cegedim.com/solutions/data/Pages/default.aspx) served as the sampling frame. Directories of health centres, drawn from official webs, registries, and addresses of health administrations and professional organizations in the public and private sectors, were used to make up the physicians panel or universe of doctors potentially participating in the study. A total of 399 298 physicians are included in the OneKey database for the 12 Selection criteria for patients were being 50 years of age or older, free from clinical CVD, and with at least one of the classic CVD risk factors (hypertension, dyslipidaemia, diabetes, obesity, or tobacco consumption documented in the clinical record). Physicians were given a randomisation list to select a sample of patients cited for medical visit each day during the study period. Approximately 12 300 patients were invited to participate, of whom 7641 (62%) accepted.
The study protocol was approved by the appropriate clinical research Ethics Committee in each participating country. All patients provided written informed consent.
Assessment of cardiovascular disease risk factors
Patient information was collected from clinical records, and from an ad hoc standardized interview, a physical exam, and a fasting blood sample. Information on smoking and physical activity was obtained from patient interviews. Hypertension, dyslipidaemia, diabetes, and obesity were considered present if their diagnosis was documented in the medical record. The prescription of specific medical advice for hypertension, dyslipidaemia, diabetes, obesity, and smoking was ascertained by questionnaire addressed to the physician.
Physical examination included height and weight measurement using calibrated scales and stadiometers, with participants wearing light clothing and without shoes. 2, 24 Waist circumference (WC) was measured to the nearest 0.1 cm, at the midpoint between the lowest rib and the iliac crest with patients unclothed to the waist. Blood pressure (BP) was determined in standardized conditions, using calibrated mercury sphygmomanometers or validated automated devices, and appropriate-size cuffs. 2, 24 The average of three readings was used for analyses. A 12 h fasting blood sample was obtained on the day of physical examination or, if not possible, on the following day. Blood samples were sent to a central laboratory in Belgium for the analysis (The Bio Analytical Research Corporation, www.barclab.com). High-density lipoprotein cholesterol was measured by a modified enzymatic method (Roche P-Modular analyzer), total cholesterol by the CHOD-PAP method (Roche P-Modular), triglycerides by the GPO-PAP method (Roche P-Modular), and low-density lipoprotein cholesterol was calculated by the Friedewald formula. Glycosylated haemoglobin (HbA1c) was measured by ion-exchange (high-performance liquid chromatography/Menarini 8160).
In each country, a 10% random sample of all study centres underwent a site visit for data monitoring and audit to ensure data quality.
Treatment goals for cardiovascular disease risk factors
Treatment goals were evaluated in accordance with the Fourth European guidelines based on data from the physical examination or from the blood sample drawn at the study visit. 2 
Statistical analyses
The main outcome was the proportion of patients achieving treatment goals. Generalized mixed linear models were used to identify clinical variables associated with attainment of treatment goals for CVD risk factors. Regression models included sex, age, smoking, hypertension, dyslipidaemia, diabetes, obesity, physical inactivity, and country (random effect variable). Also, control of CVD risk factors in each country was compared with the average across participating countries, using logistic regression models adjusted for sex and age. All variables were modelled as categorical with dummy terms. Statistical significance was set at two-tailed P , 0.05. Analyses were performed with the SAS system (version 9.1, SAS Institute, Inc., Cary, NC, USA).
Results
The average (SD) age of participating patients was 63.2 (+8.9) years. Also, 48.4% of participants were men, 48.4% had a history of smoking (21.3% current smokers), 72.7% had hypertension, 57.7% had dyslipidaemia, 26.8% had type 2 diabetes, 43.6% were obese, 19.8% were physically inactive, and 50.2% did light physical activity only (activity during most weeks, not causing shortness of breath, increased heart rate and perspiration) ( Table 1) . About 40% of patients was at high CVD risk despite being or not being treated, with a between-country range (BCR) of 29 -57.3% ( Table 1) .
Achievement of treatment goals
Among 5559 patients with hypertension, 94.2% were on antihypertensive drugs. Target BP was reached by 38.8% of treated patients (BCR: 32.1-47.5%) ( Table 2) . Of 4407 patients with dyslipidaemia, 74.4% were treated with lipid-lowering drugs. Target total cholesterol and LDL-cholesterol levels were reached by 41.2% of treated patients (BCR: 24.3-68.4%) ( Table 2 ). The proportion of patients attaining the total cholesterol target alone was 43.3% (BCR: 27.6-70.8%).
Among 2046 patients with type 2 diabetes, 87.2% were treated with antidiabetic drugs. The recommended HbA1c level of ,6.5% was reached by 36.7% of treated patients (BCR: 23.4-48.4%) ( Table 2 ). In addition, 20% of treated patients achieved the target FPG of ,6.1 mmol/L (BCR: 6.0 -43.1%). Only 7.2% of treated patients with diabetes achieved both their target FPG and HbA1c levels.
Of 3324 patients with a diagnosis of obesity prior to study enrolment, 92.2% were on lifestyle treatment (weight reduction advice) ( Table 2 ). 
Remaining cardiovascular disease risk in patients achieving treatment goals
Among the 2032 hypertensive patients with BP controlled on drug treatment, 34.8% remained at high CVD risk (Table 3) . Likewise, 39.2% of the 1350 controlled dyslipidaemic patients, 38% of the 655 controlled diabetic patients, and 39% of the 738 controlled obese patients also still had a high residual CVD risk, with wide between-country ranges.
Lifestyle medical advice
Almost 89% of smokers were asked about their smoking habit, but only 64% had their degree of addiction assessed, and as few as 38.8% agreed on a smoking cessation strategy ( Table 4) . Weight reduction was the medical advice most frequently given to obese patients. Advice on a healthy diet (low in fat and rich in vegetables and fruit) was provided to .80% of patients, but only half of them were given written dietary advice and as few as one-quarter to one-third was referred to a dietician. Appropriate advice on physical activity (at least 30 min, with moderate or vigorous intensity, on most days of the week) was given to 80% of physically inactive patients. Between-country range in lifestyle medical advice was wide.
Variables associated with achievement of treatment goals
Female patients were less likely to achieve risk factor goals in dyslipidaemia and men less likely to attain their BP goal ( Table 5) . Patients over 65 years were more likely to achieve control of dyslipidaemia and obesity. Control of hypertension was much lower in diabetic patients and in those with obesity. Control of diabetes was lower in dyslipidaemic patients, and control of obesity was lower in those with hypertension, diabetes, and physical inactivity. Lastly, countries in Eastern Europe showed generally lower than average attainment of treatment goals for most CVD risk factors ( Table 6 ).
Discussion Principal findings
The EURIKA study is the first to attempt a large-scale comparative assessment of the status of primary CVD prevention among patients with varying degrees of CVD risk across Europe. Its main finding was that, currently in 2010, the control of CVD risk factors in primary prevention is generally poor. Less than half of hypertensive and dyslipidaemic patients attained treatment goals, and only one-third of patients with diabetes met the HbA1c goal. We also observed that the no-smoking advice was the least frequently provided professional advice, that 
Reasons for not achieving treatment goals
In multivariate analyses, treated diabetes and obesity were associated with poor control of hypertension, in line with previous studies. 27 Despite most obese patients receiving medical advice to follow a low-calorie diet and try to lose weight, many were likely not to comply, which may partly account for the low rate of obesity control. However, the EUROACTION study has shown that a nurse-led, multi-disciplinary team approach can yield significant lifestyle improvements and risk factor reductions in coronary patients and those at risk of developing CVD. 28 In addition, treated dyslipidaemic women showed worse control, regardless of CVD risk and country. This could be due to a less rigorous approach towards women by clinicians, though earlier studies have reported conflicting results. 29 Anyway, clinicians should make a specific point of assessing risk factors in women. Lastly, the between-country variation in attainment of treatment targets may be due to differences in patients' clinical and socioeconomic characteristics, in adherence to CVD prevention guidelines, and in healthcare systems between countries. Countries in Eastern Europe showed generally lower than average attainment of treatment goals for most CVD risk factors. Patients in Russia had a lower than average level of drug treatment for hypertension and dyslipidaemia, and this may partially explain the lower control of BP and cholesterol. Also, a higher level of diabetes and physical inactivity was observed in patients in Turkey, which may be related to the lower control of obesity. Likewise, patients in Spain had a higher proportion and lower control of dyslipidaemia than other countries, and patients in Sweden had a higher proportion and lower control of hypertension. The wide range of drug treatments used across countries suggests important differences in drug prescription policies or market penetration. Lifestyle interventions also widely varied among countries. Improvement in smoking cessation strategies, effective healthy diet advice, weight reduction advice in obese patients, and physical activity advice may substantially increase risk factors control in countries performing poorly.
Comparison with other studies
The EUROASPIRE III primary-prevention arm determined whether the 2003 guidelines on CVD prevention were followed in high-risk patients studied in 2006. 19, 22 EURIKA, which assessed the 2007
European guidelines in 2010 in patients with a wide range of CVD risk, found higher levels of hypertension and dyslipidaemia control, but lower level of diabetes control than EUROASPIRE. Nevertheless, no formal direct comparison can be made between studies due to different patient populations and protocols. In addition, EURIKA included determination of LDL cholesterol, and not only total cholesterol in contrast with other major cross-national initiatives. 16 -19 The use of total cholesterol as the only parameter for assessment of dyslipidaemia and the sole treatment target overestimates the number of patients with lipids at goal. This translates in practice into 1 million-treated dyslipidaemic patients who might be falsely considered to be adequately controlled in the participating countries (data not shown), and may preclude optimal treatment of patients in whom the LDL-c remains uncontrolled.
Strengths and limitations
The use of common and standardized procedures for data collection allowed for a fair comparison of results across European countries. The use of a central laboratory for blood analyses, including LDL cholesterol and HbA1c, was also an important strength of the EURIKA study in comparison with other similar research initiatives. A limitation of EURIKA is that the OneKey database, which is the largest available database of practicing physicians in Europe, is not statistically fully representative of all European physicians. The percentage of physicians in the various participating countries who are included on this database ranges from 10% in Russia to 50% in Spain. It is feasible that physicians participating in a study of this nature may be more aware of and more successful at achieving treatment goals than those who did not participate. Even so, it is clear that control of CVD risk factors can still be improved substantially. Also, the inclusion period was short (a few months), so that frequent users of health services might have been overrepresented in the study sample. By the same token, less frequent clinic attenders and 'at risk' patients with undetected risk factors who have never attended for formal assessment are likely to be underrepresented in our cohort. However, the large number of practitioners included, the coverage of all relevant work-settings involved in CVD prevention, and the random selection of study patients suggest that EURIKA provides a comprehensive picture of the status of primary CVD prevention in clinical practice across Europe.
In addition, there is concern that the SCORE equation may overestimate risk in many Western European countries with decreasing secular trends in CVD mortality as well as in elderly patients. 30 Conversely, the SCORE equation may underestimate risk in Russia and other Eastern European countries that are experiencing extremely high rates of CVD mortality. In particular, in Russia the calculated CVD risk was lower than expected. This was partially due to the fact that study participants in Russia had the lowest mean age and the lowest percentage of men among the EURIKA countries but also raises an important question regarding the accuracy and representativeness of the current SCORE system for CVD risk assessment in very high-risk countries. Also, risk estimation in the elderly remains a challenge, and the optimal threshold for defining high CVD risk in those ≥65 years needs further investigation. 25, 26 Lastly, we were only able to assess current level of residual risk in relation to risk factor control in this cross-sectional survey of patients with CVD risk factors. Additional work would be required to address the important question of the effectiveness of risk factor control in relation to the level of global risk at the time of diagnosis or initiation of preventive treatment. However, we have calculated that among the 2443 patients with a diagnosis of hypertension or dyslipidaemia with complete information on systolic BP and total cholesterol at diagnosis time (pre-treatment levels), 41% of treated hypertensive patients (26% of high risk and 45% of low risk) were at BP goal, and 42% of treated dylipidaemic patients (41% of high risk and 42% of low risk) were at LDL goal. Also, though we do not know the time frame for risk factor treatment, the mean duration of the current medication for most CVD risk factors was 4-5 years, with rather narrow between-country range (data not shown).
Clinical implications
The EURIKA study has shown that: (i) many patients with treated CVD risk factors remained inadequately controlled, (ii) a large proportion of patients achieving treatment goals for individual risk factors remained at high-residual CVD risk, and (iii) lifestyle interventions are generally not well implemented. Finally, the large differences observed in risk factors control across countries suggest additional room for improvement in countries performing poorly. We support a more comprehensive application of the recommendations of the European guidelines for CVD primary prevention to address the observed treatment gaps.
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